Optimizing antiseizure medication treatment in glioma patients with epilepsy

Meer, P.B. van der

CHAPTER 4

First-line levetiracetam versus enzyme-inducing antiseizure medication in glioma patients with epilepsy

Pim B. van der Meer
Marta Maschio
Linda Dirven
Martin J.B. Taphoorn
Johan A.F. Koekkoek
Italian League Against Epilepsy BTRE Study Group

Abstract

Objective
This study aimed to directly compare the effectiveness of first-line monotherapy levetiracetam (LEV) versus enzyme-inducing antiseizure medications (EIASMs) in glioma patients.

Methods
In this nationwide retrospective observational cohort study grade 2-4 glioma patients were included, with a maximum duration of follow-up of 36 months. Primary outcome was ASM treatment failure for any reason and secondary outcomes were treatment failure due to uncontrolled seizures and due to adverse effects. For estimation of the association between ASM treatment and ASM treatment failure, multivariable cause-specific cox proportional hazard models were estimated, adjusting for potential confounders.

Results
In the original cohort a total of 808 brain tumour patients with epilepsy were included, of which 109 glioma patients were prescribed first-line LEV and 183 glioma patients first-line EIASMs. The EIASMs group had a significantly higher risk of treatment failure for any reason compared to LEV (adjusted hazard ratio [aHR]=1.82 [95%CI=1.20-2.75], p=0.005). Treatment failure due to uncontrolled seizures did not differ significantly between EIASMs and LEV (aHR=1.32 [95%CI=0.78-2.25], p=0.300), but treatment failure due to adverse effects differed significantly (aHR=4.87 [95%CI=1.89-12.55], p=0.001).

Significance
In this study it was demonstrated that LEV had a significantly better effectiveness (i.e. less often ASM treatment failure for any reason or due to adverse effects) compared to EIASMs, supporting the current neuro-oncology guideline recommendations to avoid EIASMs in glioma patients.

Key points
- Levetiracetam had favourable tolerability compared to enzyme-inducing antiseizure medications.
- All different enzyme-inducing antiseizure medications had considerably worse tolerability than levetiracetam.
- Levetiracetam and enzyme-inducing antiseizure medications had similar efficacy.

Introduction

Clinical management of seizures is a vital aspect in the disease trajectory of many patients with a brain tumour, especially patients with glioma. Antiseizure medication (ASM) treatment is generally advised after a first seizure has occurred.[1] However, with about 30 different types of ASMs to choose from, ASM selection can be complicated.[2, 3] There is a general lack of randomised controlled trials (RCTs) in brain tumour-related epilepsy to help guide clinicians in their choice. Only two small ASM RCTs have been conducted in brain tumour patients with epilepsy, comparing levetiracetam (LEV) with pregabalin and LEV with phenytoin (PHT).[4, 5] In both studies LEV showed good efficacy and tolerability,[4, 5] but due to the small sample sizes these RCTs cannot provide a definitive answer whether LEV is the preferred ASM in brain tumour patients. A recent large retrospective observational study compared first-line LEV with valproic acid (VPA) in glioma patients and showed LEV has a more favourable efficacy, while the two ASMs have a similar level of toxicity.[6] An extensive longitudinal cohort study in non-brain tumour-related epilepsy (BTRE) patients, spanning ASM treatment over four decades, could not establish an improved tolerability of second-generation (e.g. LEV and pregabalin [PGB]) compared to first-generation ASMs (e.g. VPA and carbamazepine [CBZ]).[7] Although expert-opinion argues improved tolerability of newer ASMs,[8-10] this can be disputed.[6, 7] Prescribing enzyme-inducing antiepileptic drugs (EIASMs), such as (older) agents like PHT, phenobarbital (PB), CBZ, and oxcarbazepine (OXC) in glioma patients is generally discouraged.[1, 8] This is mainly due to their metabolisation in the liver and induction of cytochrome P450 (CYP450)-dependent hepatic enzymes, thereby increasing their own metabolism and of systemic agents frequently prescribed in glioma patients.[8] The most commonly prescribed systemic antitumour therapy in glioma patients are PCV (combination of procarbazine, CCNU [lomustine], and vincristine), single-agent lomustine, and temozolomide.[1] While EIASMs affect pharmacokinetics of lomustine and vincristine, this is not true for procarbazine, bevacizumab, and temozolomide.[8, 11] Since only a minority of glioma patients treated with ASMs receive lomustine and/or vincristine, while the majority of glioma patients are prescribed temozolomide,[6, 12, 13] conventional strategy that EIASMs should be discouraged in all glioma patients seems a bit extreme. Despite the possible interactions between EIASMs and antitumour treatment in glioma patients with epilepsy, there is currently limited data that discourage the use of EIASMs due to lack of effectiveness compared to non-EIASMs. Effectiveness encompasses both efficacy and tolerability of the treatment and is reflected in its retention rate or its inverse treatment failure rate for any reason (i.e., mainly due to inefficacy or intolerable adverse effects).[14] The International League Against Epilepsy (ILAE) recommends the retention rate (or its inverse) as primary outcome for clinical studies in epilepsy research.[15]

A systemic review showed the EIASM PHT, together with LEV and PGB, had the highest efficacy in glioma patients. However, of all ASMs studied in the systematic review PHT and PB had the highest treatment failure due to adverse effects.[16] While some EIASMs may be effective in the treatment of brain tumour-related epilepsy, it is unclear if these agents are more effective than the most commonly prescribed ASM in the glioma population, LEV. This retrospective observational study aimed to directly compare the effectiveness of first-line monotherapy LEV versus EIASMs in glioma patients.

Methods

Study population and procedures

This study population is a subset of a previously published study by members of the Italian League Against Epilepsy Brain Tumor-Related Epilepsy Study Group. A more detailed description of the methodology has been described elsewhere.[17] In short, a nationwide, multicenter retrospective observational cohort study was conducted and all 35 centers adhering to the study group were invited to participate on a voluntary basis. Consecutive patients with a histological or radiological diagnosed grade 2-4 glioma ([anaplastic] astrocytoma, [anaplastic] oligoastrocytoma, [anaplastic] oligodendroglioma, or glioblastoma), seen by a physician and followed for at least one month between January 1st, 2010 and December 31st, 2011, seizures in close temporal association with the tumour diagnosis, and first-line treatment with levetiracetam or an EIASM (CBZ, OXC, PB, or PHT) were included. Patients with a history of non-brain tumour-related epilepsy were excluded. Medical charts of patients were examined to extract baseline sociodemographic data, tumour characteristics, antitumour treatment information, seizure characteristics and ASM treatment information. The study was approved by the Ethical Committee of Regina Elena National Cancer Institute.

Outcomes

Primary outcome was time to treatment failure, which was defined as the time from initiation of first-line ASM monotherapy until treatment failure, with a maximum follow-up duration of 36 months. ASM treatment failure was defined as discontinuation or the add-on of an additional ASM because of intolerable adverse effects, uncontrolled seizures, or other reasons. Secondary outcome was time to treatment failure with regard to specific reasons of treatment failure (i.e., due to uncontrolled seizures, due to adverse effects, and due to other reasons).

Statistics

Multivariable Cox proportional hazard models were estimated to study the association between the risk factor ASM treatment and treatment failure, adjusted for potential

confounders. In case of cause-specific reasons for treatment failure, these specific reasons should be handled as separate competing risks. Hence, a patient who experiences treatment failure due to uncontrolled seizures can no longer experience treatment failure due to adverse effects on their first-line ASM. Two competing risk models were estimated: 1) treatment failure due to uncontrolled seizures (event of interest) versus treatment failure due to adverse effects and other reasons; 2) treatment failure due to adverse effects (event of interest) versus treatment failure due uncontrolled seizures and other reasons. The proportional hazards assumption was checked based on Schoenfeld residuals, nonlinearity by Martingale residuals, and influential observations by deviance residuals. The following baseline covariates, which were regarded as potential confounders were selected based on pre-existing literature and included in the multivariable Cox proportional hazard models: age, sex, tumour grade, surgical resection, tumour involvement in the temporal and frontal lobe, karnofsky performance status, size of epilepsy center, seizure type, and ASM started prophylactically. Data were analysed using *SPSS* version 25.0. A p-value of <0.05 was considered statistically significant.

Results

The original study population consisted of 808 patients.[17] Within this cohort n=292 (36%) glioma patients were recruited who used LEV or EIASMs as first-line ASM. Out of these 292 patients, n=109 (37%) patients used LEV, n=41 (14%) patients CBZ, n=49 (17%) patients OXC, n=74 (25%) patients PB, and n=19 (7%) patients PHT. Baseline cohort characteristics of patients on first-line monotherapy LEV or EIASMs are reported in Table 1. Patients in the LEV versus the EIASMs group had significantly more often a high-grade glioma (83% [91/109] versus 68% [124/183], p=0.013) and were treated in large epilepsy centers (94% [103/109] versus 84% [153/183], p=0.006), but had less often had surgical resection (40% [44/109] versus 57% [104/183], p=0.005) at baseline.

Time to treatment failure LEV versus EIASMs
Of the patients who were prescribed first-line monotherapy LEV, 30% (33/109) showed treatment failure for any reason in the 36 months follow-up period, while this was 68% (125/183) for patients prescribed EIASMs. At 6 and 12 months treatment failure for any reason was 20% (22/109) and 26% (28/109) for LEV versus 34% (63/183) and 47% (86/183) for EIASMs, respectively. Patients prescribed EIASMs had a significantly higher risk of treatment failure for any reason compared to LEV (adjusted hazard ratio [aHR]=1.82 [95%CI=1.20-2.75], p=0.005 [Table 2]).

Table 1. Demographic characteristics of the patients at baseline

Characteristics	Antiseizure medication treatment		
	LEV	EIASMs	P-value
Patients included, no. (%)	109	183	
Age, no. (%)			0.180
≤40 years	20 (18)	46 (25)	
>40 years	89 (82)	137 (75)	
Sex, no. (%)			0.100
Male	56 (51)	112 (61)	
Female	53 (49)	71 (39)	
Tumor grade and pathology, no. (%)			0.013
Grade 2 glioma	18 (17)	59 (32)	
Diffuse astrocytoma	8 (7)	27 (15)	
Oligodendroglioma	6 (6)	24 (13)	
Oligoastrocytoma	4 (4)	8 (4)	
Grade 3 glioma	34 (31)	46 (25)	
Anaplastic astrocytoma	17 (16)	19 (10)	
Anaplastic oligodendroglioma	6 (6)	16 (9)	
Anaplastic oligoastrocytoma NOS	11 (10)	11 (6)	
Grade 4 glioma			
Glioblastoma	57 (52)	78 (43)	
Surgical resection, no. (%)			0.005
Yes	44 (40)	104 (57)	
No (including biopsy)	64 (59)	76 (42)	
Unknown	1 (1)	3 (2)	
Tumour located in the temporal lobe, no. (%)			0.339
Yes	33 (30)	46 (25)	
No	75 (69)	136 (74)	
Unknown	1 (1)	1 (1)	
Tumour located in the frontal lobe, no. (%)			0.908
Yes	49 (45)	81 (44)	
No	59 (54)	101 (55)	
Unknown	1 (1)	1 (1)	
Karnofsky Performance Status, no. (%)			0.256
≥70	81 (74)	139 (76)	
<70	25 (23)	32 (17)	
Unknown	3 (3)	12 (7)	
Size of epilepsy center, no. (%)			0.006
≥20	103 (94)	153 (84)	
<20	6 (6)	30 (16)	
Seizure type, no. (%)			0.483
Focal	57 (52)	92 (50)	
Focal to bilateral tonic-clonic[a]	42 (39)	81 (44)	
Unknown	10 (9)	10 (5)	
ASM started prophylactically, no. (%)			0.423
Yes	40 (37)	79 (43)	
No	59 (54)	95 (52)	
Unknown	10 (9)	9 (5)	

[a]Patients had either solely focal to bilateral tonic-clonic seizures or both focal and focal to bilateral tonic-clonic seizures; ASM=antiseizure medication; EIASMs=enzyme-inducing antiseizure medications; LEV=levetiracetam; No.=number of patients; PCV= procarbazine, lomustine, and vincristine

Table 2. Cause-specific hazard ratios of time to treatment failure for any reason

Parameter		uHR (95% CI)	p-value	aHR (95% CI)	p-value
ASM treatment	LEV (ref.)				
	EIASMs	2.30 (1.57-3.38)	<0.001	1.82 (1.20-2.75)	0.005
Age		1.00 (0.99-1.01)	0.873	1.00 (0.98-1.01)	0.842
Sex	Male (ref.)				
	Female	1.00 (0.73-1.38)	0.979	1.17 (0.81-1.67)	0.404
Tumour grade	2 (ref.)				
	3	0.62 (0.41-0.93)	0.020	0.84 (0.53-1.33)	0.453
	4	0.71 (0.49-1.03)	0.068	0.81 (0.51-1.27)	0.355
Surgical resection	No (including biopsy, ref.)				
	Yes	1.46 (1.06-2.01)	0.021	1.21 (0.84-1.74)	0.317
Tumour involvement in the temporal lobe	No (ref.)				
	Yes	0.67 (0.46-0.99)	0.042	0.65 (0.41-1.02)	0.062
Tumour involvement in the frontal lobe	No (ref.)				
	Yes	0.90 (0.66-1.23)	0.502	0.76 (0.52-1.11)	0.159
Karnofsky Performance Status	≥70 (ref.)				
	<70	0.83 (0.53-1.29)	0.403	0.91 (0.54-1.51)	0.706
Size of epilepsy center	≥20 (ref.)				
	<20	1.86 (1.22-2.83)	0.004	1.94 (1.08-3.47)	0.026
Seizure type	Focal (ref.)				
	Focal to bilateral tonic clonic[a]	0.91 (0.66-1.26)	0.580	1.10 (0.77-1.58)	0.594
ASM started prophylactically	No (ref.)				
	Yes	0.97 (0.70-1.34)	0.866	0.96 (0.66-1.37)	0.805

[a]Included either solely focal to bilateral tonic-clonic seizures or both focal and focal to bilateral tonic-clonic seizures; aHR=adjusted hazard ratio; ASM=antiseizure medication; CI=confidence interval; EIASM=enzyme-inducing antiseizure medication; LEV=levetiracetam; Ref.=reference; uHR=unadjusted hazard ratio

4

Main reason of treatment failure in the 36 months follow-up period for LEV and EIASMs was uncontrolled seizures (18% [20/109] versus 36% [65/183] patients), followed by adverse effects (6% [6/109] versus 22% [41/183] patients), and other reasons (6% [7/109] versus 10% [19/183] patients). Patients prescribed EIASMs did not have a significantly higher risk of treatment failure due to uncontrolled seizures compared to LEV (aHR=1.32 [95%CI=0.78-2.25], p=0.300 [Supplementary Table 1]), but had a higher risk of treatment failure due to adverse effects (aHR=4.87 [95%CI=1.89-12.55], p=0.001 [Supplementary Table 2]), while the number of events was too low to estimate the aHR for treatment failure due to other reasons. Percentages of treatment failure for any reason, due to adverse effects, due to uncontrolled seizures, and due to other reasons at 6, 12, and 36 months for LEV and the EIASMs separately (CBZ, OXC, PB, and PHT) are reported in Table 3. The number of events were too low to estimate the aHR of these different EIASMs compared to LEV for treatment failure.

Table 3. Percentages of treatment failure for the enzyme-inducing antiseizure medications at 6, 12, and 36 months

	Antiseizure medications				
	LEV, n=109	CBZ, n=41	OXC, n=49	PB, n=74	PHT, n=19
Treatment failure for any reason					
6 months, no. (%)	22 (20)	10 (24)	13 (27)	28 (38)	12 (63)
12 months, no. (%)	28 (26)	19 (46)	18 (37)	37 (50)	12 (63)
36 months, no. (%)	33 (30)	32 (78)	26 (53)	51 (69)	16 (84)
Treatment failure due to uncontrolled seizures					
6 months, no. (%)	13 (12)	1 (2)	6 (12)	10 (14)	6 (32)
12 months, no. (%)	18 (17)	6 (15)	11 (22)	17 (23)	6 (32)
36 months, no. (%)	20 (18)	15 (37)	17 (35)	25 (34)	8 (42)
Treatment failure due to adverse effects					
6 months, no. (%)	5 (5)	7 (17)	6 (12)	15 (20)	1 (5)
12 months, no. (%)	6 (6)	9 (22)	6 (12)	17 (23)	1 (5)
36 months, no. (%)	6 (6)	10 (24)	8 (16)	21 (28)	2 (11)
Treatment failure due to other reasons					
6 months, no. (%)	4 (4)	2 (5)	1 (2)	3 (4)	5 (26)
12 months, no. (%)	4 (4)	4 (10)	1 (2)	3 (4)	5 (26)
36 months, no. (%)	7 (6)	7 (17)	1 (2)	5 (7)	6 (32)

CBZ=carbamazepine; LEV=levetiracetam; OXC=oxcarbazepine; PB=phenobarbital; PHT=phenytoin

Discussion

In this retrospective observational cohort study the effectiveness of first-line monotherapy LEV was compared to EIASMs as a group in glioma patients with epilepsy. We demonstrated that LEV had a significantly lower treatment failure for any reason versus EIASMs, meaning a more favourable effectiveness. This difference in effectiveness was (mainly) attributable to a better tolerability, while no significant differences were found between the two groups with regard to efficacy (i.e., treatment failure due to uncontrolled seizures). Treatment failure due to adverse effects at 36 months ranged from 11% to 26% between the different EIASMs, but all considerably higher than LEV (6%). LEV has thus shown improved tolerability over EIASMs in glioma patients in our study. Our findings are in line with current guidelines in which LEV is considered one of the preferred first-line ASMs in glioma patients with epilepsy without a history of psychiatric disease (e.g., anxiety disorder).

Treatment failure (due to adverse effects) of EIASMs tended to be similarly high in other studies examining EIASMs in glioma patients. In a systematic review evaluating ASMs in glioma patients the two ASMs with the highest treatment failure for any reason (64%, with unknown duration of follow-up) were CBZ and PB, which was similar in our study. The 12-month treatment failure due to adverse effects for CBZ was 26% versus 22% in our study, but remarkable is the high 12-month treatment failure due to adverse effects for PHT of 34% versus 5% in our study.[16] This might be explained by the relatively high treatment failure due to other reasons for PHT in our study, possibly reflecting discontinuation of the ASM due to interactions with systemic treatment.

In a previous large Dutch observational cohort study first-line monotherapy LEV showed superior effectiveness compared to VPA in the glioma population. The difference in effectiveness between these two agents was attributable due to a difference in efficacy, while tolerability was similar with treatment failure due to adverse effects at 12 months of 14% for LEV versus 15% for VPA.[6] Despite the Italian cohort from this study appearing relatively similar to the Dutch cohort, with newly diagnosed glioma patients prescribed first-line monotherapy ASM treatment, treatment failure due to adverse effects of LEV at 12 months differ considerably between the Dutch and Italian cohort (14% versus 6%), respectively.[6] This difference in tolerability of LEV between the cohorts is not entirely clear. There is a certain degree of subjectivity in attributing experienced adverse effects by patients to LEV, especially in glioma patients undergoing antitumour treatment. It might be that Dutch neuro-oncology professionals attribute more frequently experienced adverse effects to LEV (e.g., fatigue and somnolence) instead of the disease and antitumour treatment). If the suspicion arises a medicine caused an adverse effect the Naranjo scale can be used to assess the probability of the causality. The Naranjo scale is a 10-item questionnaire to assess causality for adverse drug reactions and can assist in whether changing the ASM treatment regimen is justified.[18]

Currently, guidelines in neuro-oncology discourage prescribing EIASMs in BTRE patients, because of their drug-drug interaction with certain chemotherapeutic agents and their supposed worse tolerability compared to newer ASMs such as LEV.[1, 19] In a recent international survey it was found that only about 5% of neuro-oncology clinicians view an EIASM as the first choice ASM in brain tumour patients with mainly focal seizures, mainly bilateral tonic-clonic seizures or most effective in reducing seizure frequency, while none of the clinicians view an EIASM as best tolerable ASM.[20] Our data confirms EIASMs cause significantly more often treatment failure due to adverse effects compared to LEV, while efficacy seems similar. The worse tolerability, drug-drug interactions, and the high number of potential alternative ASMs make EIASMs in glioma patients less attractive treatment candidates and should be avoided. A commonly chosen equivalent first choice ASM to LEV is lamotrigine (LTG) in BTRE patients.[20] The recent SANAD II study including n=990 non-BTRE patients demonstrated inferiority of LEV compared to LTG, and concluded that LTG should remain first-line treatment for patients with focal epilepsy. Among other worse outcomes, LEV had significantly higher treatment failure for any reason and treatment failure due to adverse effects, but not treatment failure due to uncontrolled seizures.[21] Findings from non-BTRE studies are not necessarily directly applicable to BTRE patients, but these favourable results with regard to LTG warrant evaluating LTG in BTRE patients. Especially given the lack of studies evaluating the efficacy of LTG in BTRE patients.[16]

Limitations

Not all relevant data could be collected, hampering certain important analyses. For example, the date of chemotherapy and radiotherapy were missing and therefore the estimates could not be adjusted for these relevant confounders in the Cox regression analyses. This also applies to date of death, hampering taking death into account as competing event in a competing risk model. In addition, no detailed information was collected with regard to the specific adverse effects, so nothing can be said of what type of intolerable adverse effects seem to occur in glioma patients prescribed EIASMs. The type of intolerable adverse effects and data on whether the intolerable adverse effects improved after discontinuation of the ASM could have given more insight in the causality of ASM and/or the interaction with other medication (e.g., chemotherapy) and the intolerable adverse effects. In addition, no data on titration and dosage at moment of treatment failure was collected. Titration rate can have a meaningful relationship with tolerability, which might have affected results. Despite the reasonable size of the entire cohort, several types of EIASMs had to be combined to perform meaningful analyses, given the small number of patients per different EIASM. Therefore, results largely apply to EIASMs as a group, while there are certainly differences between the individual EIASMs (e.g., OXC is only a weak enzyme-inducer). Primary prophylaxis of ASM in glioma patients is discouraged by international and national Italian neuro-oncology guidelines, including Glantz et al. (2000),[22] Maschio et al. (2019),[23] Walbert

et al. (2021),[24] and Maschio et al. (2019).[23] Still ASM primary prophylaxis was initiated in ~40% of patients in our study. This is in line with the findings from an international survey in which 50% of Italian neuro-oncology professionals reported prescribing ASM solely as primary prophylaxis.[20] Unfortunately, due to the retrospective design of our study, the reasons behind the prescription of primary prophylaxis contrary to the guidelines are unclear, but likely to the trade-off between the risk of adverse effects (non-maleficence) and the benefit of preventing seizures (beneficence) was in favour of ASM primary prophylaxis. We do acknowledge current evidence for primary prophylaxis is minimal and faulty and hopefully the ongoing SPRING (prophylactic levetiracetam versus no prophylactic ASM in seizure-naïve glioma patients) trial might elucidate this matter.[25] A relatively high number of patients were prescribed barbiturate PB, which has been used for seizure control >100 years, but is nowadays rarely prescribed as first-line ASM in glioma patients in most countries.[6, 16, 20] PB was among the most frequently used ASMs during the early 2000s. Factors contributing to its widespread use were its low cost, its well-known safety profile, and ample experience among treating physicians in prescribing PB.[26-28]

Conclusion

Our study supports the recommendation to avoid prescribing EIASMs in glioma patients. LEV is the most frequently prescribed (first-line) ASM in the glioma population and given the available evidence this seems justified. However, comparative efficacy RCTs in glioma patients are currently lacking and trials comparing first-line LEV with other non-EIASMs (e.g., lacosamide or LTG) are warranted.

Ethics committee approval

The institutional review board approved the study.

Data availability

Data are available from the corresponding author upon reasonable request.

References

1. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma The Lancet Oncology. 2014 Aug;15:e395-403.

2. Brodie MJ, Sills GJ. Combining antiepileptic drugs—Rational polytherapy? Seizure. 2011 2011/06/01;20:369-375.

3. Löscher W, Klein P. The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond CNS Drugs. 2021 Sep;35:935-963.

4. Lim DA, Tarapore P, Chang E, Burt M, Chakalian L, Barbaro N, et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study Journal of neuro-oncology. 2009 Jul;93:349-354.

5. Rossetti AO, Jeckelmann S, Novy J, Roth P, Weller M, Stupp R. Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study Neuro-oncology. 2014 Apr;16:584-588.

6. van der Meer PB, Dirven L, Fiocco M, Vos MJ, Kouwenhoven MCM, van den Bent MJ, et al. First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid Epilepsia. 2021;62:1119-1129.

7. Alsfouk BAA, Brodie MJ, Walters M, Kwan P, Chen Z. Tolerability of Antiseizure Medications in Individuals With Newly Diagnosed Epilepsy JAMA neurology. 2020;77:574-581.

8. Weller M, Stupp R, Wick W. Epilepsy meets cancer: when, why, and what to do about it? The Lancet Oncology. 2012 Sep;13:e375-382.

9. Armstrong TS, Grant R, Gilbert MR, Lee JW, Norden AD. Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy Neuro-oncology. 2016 Jun;18:779-789.

10. French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Therapeutic Advances in Drug Safety. 2011 2011/08/01;2:141-158.

11. Bénit CP, Vecht CJ. Seizures and cancer: drug interactions of anticonvulsants with chemotherapeutic agents, tyrosine kinase inhibitors and glucocorticoids Neuro-oncology practice. 2016;3:245-260.

12. van der Meer PB, Koekkoek JAF, van den Bent MJ, Dirven L, Taphoorn MJB. Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints Journal of neuro-oncology. 2021 2021/05/01;153:89-98.

13. van der Meer P, Dirven L, Fiocco M, Vos MJ, Kouwenhoven MCM, van den Bent MJ, et al. The Effectiveness of Antiepileptic Drug Duotherapies in Patients With Glioma: A Multicenter Observational Cohort Study Neurology. 2022 Jun 8.

14. Drugs ICoA. Considerations on Designing Clinical Trials to Evaluate the Place of New Antiepileptic Drugs in the Treatment of Newly Diagnosed and Chronic Patients with Epilepsy Epilepsia. 1998;39:799-803.

15. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kalviainen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes Epilepsia. 2013 Mar;54:551-563.

16. de Bruin ME, van der Meer PB, Dirven L, Taphoorn MJB, Koekkoek JAF. Efficacy of antiepileptic drugs in glioma patients with epilepsy: a systematic review Neuro-Oncology Practice. 2021;8:501-517.

17. Maschio M, Beghi E, Casazza MML, Colicchio G, Costa C, Banfi P, et al. Patterns of care of brain tumor-related epilepsy. A cohort study done in Italian Epilepsy Center PLoS One. 2017;12:e0180470.

18. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions Clin Pharmacol Ther. 1981 Aug;30:239-245.

19. Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood Nature Reviews Clinical Oncology. 2020 2020/12/08.

20. van der Meer PB, Dirven L, van den Bent MJ, Preusser M, Taphoorn MJB, Rudá R, et al. Prescription preferences of antiepileptic drugs in brain tumor patients: an international survey among EANO members Neuro-Oncology Practice. 2021;9:105-113.

21. Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial The Lancet. 2021;397:1363-1374.

22. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcom-

4

mittee of the American Academy of Neurology Neurology. 2000 May 23;54:1886-1893.

23. Maschio M, Aguglia U, Avanzini G, Banfi P, Buttinelli C, Capovilla G, et al. Management of epilepsy in brain tumors Neurological Sciences. 2019 2019/10/01;40:2217-2234.

24. Walbert T, Harrison RA, Schiff D, Avila EK, Chen M, Kandula P, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors Neuro-oncology. 2021 Jun 26;23:1835-1844.

25. Jenkinson M, Watts C, Marson A, Hill R, Murray K, Vale L, et al. TM1-1 Seizure prophylaxis in gliomas (SPRING): a phase III randomised controlled trial comparing prophylactic levetiracetam versus no prophylactic anti-epileptic drug in glioma surgery Journal of Neurology, Neurosurgery & Psychiatry. 2019;90:e8-e8.

26. Savica R, Beghi E, Mazzaglia G, Innocenti F, Brignoli O, Cricelli C, et al. Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005 Eur J Neurol. 2007 Dec;14:1317-1321.

27. Yasiry Z, Shorvon SD. How phenobarbital revolutionized epilepsy therapy: The story of phenobarbital therapy in epilepsy in the last 100   years Epilepsia. 2012;53:26-39.

28. Iorio ML, Moretti U, Colcera S, Magro L, Meneghelli I, Motola D, et al. Use and safety profile of antiepileptic drugs in Italy Eur J Clin Pharmacol. 2007 Apr;63:409-415.

Supplementary material

Supplementary Table 1. Unadjusted and adjusted cause-specific hazard ratios of time to treatment failure due to uncontrolled seizures

Parameter[a]		Treatment failure due to uncontrolled seizures			
		uHR (95% CI)	p-value	aHR (95% CI)	p-value
ASM treatment	LEV (ref.)				
	EIASMs	1.98 (1.20-3.28)	0.008	1.32 (0.78-2.25)	0.300
Age		1.00 (0.98-1.01)	0.742	1.00 (0.98-1.02)	0.668
Tumour grade	2 (ref.)				
	3	0.63 (0.36-1.10)	0.105	0.92 (0.50-1.69)	0.782
	4	0.76 (0.46-1.26)	0.293	1.05 (0.56-1.98)	0.875
Surgical resection	No (including biopsy, ref.)				
	Yes	2.18 (1.36-3.49)	0.001	2.00 (1.18-3.39)	0.010
Tumour involvement in the temporal lobe	No (ref.)				
	Yes	0.52 (0.30-0.90)	0.020	0.61 (0.34-1.10)	0.102
Karnofsky Performance Status	≥70 (ref.)				
	<70	0.74 (0.39-1.40)	0.353	0.71 (0.34-1.48)	0.356
Size of epilepsy center	≥20 (ref.)				
	<20	2.10 (1.20-3.68)	0.010	1.97 (0.91-4.28)	0.085
Seizure type	Focal (ref.)				
	Focal to bilateral tonic clonic[b]	0.94 (0.61-1.45)	0.784	1.25 (0.78-2.02)	0.349
ASM started prophylactically	No (ref.)				
	Yes	0.90 (0.59-1.40)	0.648	0.73 (0.45-1.19)	0.209

[a]Sex and tumour involvement in the frontal lobe did not hold the proportionality assumption of the Cox regression model and were therefore stratified; [b]Included either solely focal to bilateral tonic-clonic seizures or both focal and focal to bilateral tonic-clonic seizures; aHR=adjusted hazard ratio; ASM=antiseizure medication; CI=confidence interval; EIASM=enzyme-inducing antiseizure medication; LEV=levetiracetam; Ref.=reference; uHR=unadjusted hazard ratio

Supplementary Table 2. Unadjusted and adjusted cause-specific hazard ratios of time to treatment failure due to adverse effects

Parameter[a]		Treatment failure due to adverse effects			
		uHR (95% CI)	p-value	aHR (95% CI)	p-value
ASM treatment	LEV (ref.)				
	EIASMs	4.22 (1.79-9.96)	0.001	4.87 (1.89-12.55)	0.001
Age		1.01 (0.99-1.03)	0.512	1.00 (0.98-1.03)	0.934
Sex	Male (ref.)				
	Female	1.23 (0.69-2.18)	0.484	1.10 (0.87-2.99)	0.132
Surgical resection	No (including biopsy, ref.)				
	Yes	1.23 (0.69-2.18)	0.488	0.81 (0.43-1.50)	0.496
Tumour involvement in the frontal lobe	No (ref.)				
	Yes	1.01 (0.56-1.80)	0.982	0.83 (0.44-1.54)	0.552
Karnofsky Performance Status	≥70 (ref.)				
	<70	1.06 (0.51-2.20)	0.885	1.17 (0.52-2.60)	0.707
Size of epilepsy center	≥20 (ref.)				
	<20	1.05 (0.42-2.67)	0.913	1.31 (0.39-4.38)	0.660
Seizure type	Focal (ref.)				
	Focal to bilateral tonic clonic[b]	1.13 (0.63-2.03)	0.680	1.18 (0.63-2.20)	0.611

[a]Tumour grade, tumour involvement in the temporal lobe, and ASM started prophylactically did not hold the proportionality assumption of the Cox regression model and were therefore stratified; [b]Included either solely focal to bilateral tonic-clonic seizures or both focal and focal to bilateral tonic-clonic seizures; aHR=adjusted hazard ratio; ASM=antiseizure medication; CI=confidence interval; EIASM=enzyme-inducing antiseizure medication; LEV=levetiracetam; Ref.=reference; uHR=unadjusted hazard ratio